First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC)

Karen A Autio ,Leonard Joseph Appleman ,I‐Ming Wang ,Michael T Schweizer ,Kenneth A Kern ,Tian Zhang ,Szu-Yu Tang ,Hani M Babiker ,Xinhua Zhu ,Megan M Kaneda ,Luke T Nordquist ,Jenny Zheng ,Helen Cho ,Stephane Billotte ,Nora Cavazos ,Ravi A Madan ,Nicholas J Vogelzang ,Sandip M Prasad ,Ray Li ,Orlaith Bogg ,Robert E Hollingsworth ,Kam Ming Chan ,Celestia S Higano ,Daniel P Petrylak

doi:10.1136/jitc-2022-005702

First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC)

Karen A Autio , Leonard Joseph Appleman + Show 22 more

Open Access

https://doi.org/10.1136/jitc-2022-005702

Copy DOI

Journal: Journal for ImmunoTherapy of Cancer	Publication Date: Mar 1, 2023
Citations: 8	License type: open-access

Affiliation: Memorial Sloan Kettering Cancer Center, UPMC Hillman Cancer Center, Pfizer (United States), Fred Hutch Cancer Center, University of Washington, The University of Texas Southwestern Medical Center, Southwestern Medical Center, University of Arizona, Northwell Health, Nebraska Cancer Specialists, National Cancer Institute, Comprehensive Cancer Centers of Nevada, Atlantic Health System, Morristown Medical Center, Yale Cancer Center, Yale University

#Prostate-specific Antigen #Biochemical Recurrence + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

BackgroundThis phase 1 study evaluated PF-06753512, a vaccine-based immunotherapy regimen (PrCa VBIR), in two clinical states of prostate cancer (PC), metastatic castration-resistant PC (mCRPC) and biochemical recurrence (BCR).MethodsFor dose escalation,...

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

More From: Journal for ImmunoTherapy of Cancer

Paper Title

Journal

Date

Author

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.